Zenotech Laboratories Ltd
Incorporated in 1989, Zenotech Laboratories Ltd is in the business of manufacturing biotechnology products[1]
- Market Cap ₹ 385 Cr.
- Current Price ₹ 63.1
- High / Low ₹ 108 / 52.2
- Stock P/E
- Book Value ₹ 15.8
- Dividend Yield 0.00 %
- ROCE -9.08 %
- ROE -12.2 %
- Face Value ₹ 10.0
Pros
- Company has reduced debt.
Cons
- Stock is trading at 3.99 times its book value
- Company has low interest coverage ratio.
- Company has a low return on equity of -14.8% over last 3 years.
- Debtor days have increased from 72.3 to 96.1 days.
- Company's cost of borrowing seems high
* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.
Peer comparison
Sector: Pharmaceuticals Industry: Pharmaceuticals - Indian - Formulations
Quarterly Results
Consolidated Figures in Rs. Crores / View Standalone
Profit & Loss
Consolidated Figures in Rs. Crores / View Standalone
Mar 2006 | Mar 2007 | Mar 2008 | Mar 2009 | Mar 2010 | |
---|---|---|---|---|---|
12 | 13 | 8 | 6 | 7 | |
15 | 19 | 18 | 24 | 16 | |
Operating Profit | -3 | -6 | -10 | -18 | -9 |
OPM % | -20% | -49% | -121% | -292% | -143% |
0 | 9 | 2 | 5 | 2 | |
Interest | 1 | 2 | 3 | 1 | 2 |
Depreciation | 0 | 2 | 3 | 3 | 3 |
Profit before tax | -3 | -1 | -14 | -18 | -13 |
Tax % | 6% | -250% | 17% | 0% | -0% |
-4 | 2 | -16 | -18 | -13 | |
EPS in Rs | 0.32 | -2.64 | -2.88 | -2.05 | |
Dividend Payout % | 0% | 0% | 0% | 0% | 0% |
Compounded Sales Growth | |
---|---|
10 Years: | % |
5 Years: | % |
3 Years: | -20% |
TTM: | 9% |
Compounded Profit Growth | |
---|---|
10 Years: | % |
5 Years: | % |
3 Years: | % |
TTM: | 29% |
Stock Price CAGR | |
---|---|
10 Years: | 10% |
5 Years: | 17% |
3 Years: | 4% |
1 Year: | -13% |
Return on Equity | |
---|---|
10 Years: | % |
5 Years: | % |
3 Years: | -15% |
Last Year: | -12% |
Balance Sheet
Consolidated Figures in Rs. Crores / View Standalone
Mar 2006 | Mar 2007 | Mar 2008 | Mar 2009 | Mar 2010 | |
---|---|---|---|---|---|
Equity Capital | 16 | 29 | 34 | 34 | 34 |
Reserves | 6 | 25 | 92 | 74 | 62 |
31 | 36 | 19 | 17 | 10 | |
21 | 10 | 8 | 5 | 4 | |
Total Liabilities | 74 | 100 | 153 | 131 | 111 |
16 | 60 | 61 | 62 | 71 | |
CWIP | 40 | 9 | 15 | 24 | 13 |
Investments | 0 | 0 | 0 | 0 | 0 |
19 | 30 | 77 | 45 | 27 | |
Total Assets | 74 | 100 | 153 | 131 | 111 |
Cash Flows
Consolidated Figures in Rs. Crores / View Standalone
Mar 2006 | Mar 2007 | Mar 2008 | Mar 2009 | Mar 2010 | |
---|---|---|---|---|---|
-16 | -7 | -3 | -16 | -10 | |
-56 | -15 | -67 | 20 | 29 | |
74 | 22 | 70 | -4 | -8 | |
Net Cash Flow | 2 | -0 | -0 | 1 | 11 |
Ratios
Consolidated Figures in Rs. Crores / View Standalone
Mar 2006 | Mar 2007 | Mar 2008 | Mar 2009 | Mar 2010 | |
---|---|---|---|---|---|
Debtor Days | 145 | 273 | 85 | 36 | 96 |
Inventory Days | 139 | 331 | 575 | 172 | 279 |
Days Payable | 451 | 455 | 421 | 226 | 253 |
Cash Conversion Cycle | -167 | 149 | 240 | -18 | 123 |
Working Capital Days | 55 | 279 | 196 | 250 | 286 |
ROCE % | 2% | -9% | -12% | -9% |
Documents
Announcements
-
Board Meeting Intimation for Approval Of Financial Results For The Quarter And Nine Months Ended December 31, 2024.
18 Jan - Board meeting scheduled for January 28, 2025.
-
Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations, 2018
13 Jan - Regarding Compliance Certificate under Regulation 74(5) of SEBI (DP) Regulations, 2018.
- Closure of Trading Window 27 Dec
- Compliances-Reg. 39 (3) - Details of Loss of Certificate / Duplicate Certificate 7 Nov 2024
-
Announcement under Regulation 30 (LODR)-Newspaper Publication
24 Oct 2024 - Copies of Advertisement published today i.e. October 24, 2024 for the extracts of Unaudited Financial Results of the Company for the quarter and half year …
Annual reports
-
Financial Year 2024
from bse
-
Financial Year 2023
from bse
-
Financial Year 2022
from bse
-
Financial Year 2021
from bse
-
Financial Year 2020
from bse
-
Financial Year 2019
from bse
-
Financial Year 2018
from bse
-
Financial Year 2017
from bse
-
Financial Year 2016
from bse
-
Financial Year 2015
from bse
-
Financial Year 2014
from bse
-
Financial Year 2013
from bse
-
Financial Year 2012
from bse
-
Financial Year 2011
from bse
-
Financial Year 2010
from bse
Business Overview:[1]
ZTLL is a part of Sun Pharmaceuticals Industries Ltd. It does manufacturing and marketing of pharmaceuticals and bio-pharmaceutical products. It is a pharmaceutical specialty
generic injectables company engaged in the area of manufacturing Oncology, bio-technology and General Injectables products